Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients

Clinical Microbiology and Infection

Volumn 13, Issue 3, 2007, Pages 264-268

  Greiner, W ^a   Rasch, Andrej ^a   Kohler D ^a   Salzberger, B ^b   Fatkenheuer G ^c   Leidig, M ^d  

^a BIELEFELD UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bacteraemia; Costof illness; Haemodialysis; MRSA; Renal failure; Staphyloccocus aureus

Indexed keywords

BETA LACTAMASE INHIBITOR; METICILLIN; PENICILLIN G; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; GERMANY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; STAPHYLOCOCCUS INFECTION;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 34247252566     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01622.x     Document Type: Article

References (29)

1. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346: 491-496.
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 887-892.
3. Goetz A, Posey K, Fleming J et al. Methicillin-resistant Staphylococcus aureus in the community: A hospital-based study. Infect Control Hosp Epidemiol 1999; 20: 689-691.
4. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-532.
5. Quarles LD, Rutsky EA, Rostand SG. Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 1985; 6: 412-419.
6. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993; 64: 95-100.
7. Sexton DJ. Vascular access infections in patients undergoing dialysis with special emphasis on the role and treatment of Staphylococcus aureus. Infect Dis Clin North Am 2001; 15: 731-742.
8. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol 2002; 23: 716-720.
9. Engemann JJ, Friedman JY, Reed SD et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 2005; 26: 534-539.
10. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. Epibacdial. a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876.
11. Jean G, Charra B, Chazot C et al. Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias. Nephron 2002; 91: 399-405.
12. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127: 275-280.
13. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs? Infect Control Hosp Epidemiol 1999; 20: 408-411.
14. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (suppl 2): S114-S132.
15. Edmond MB, Wallace SE, Mcclish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999; 29: 239-244.
16. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001; 22: 99-104.
17. Mchugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25: 425-430.
18. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26: 175-183.
19. Whitby M, Mclaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: A meta-analysis. Med J Aust 2001; 175: 264-267.
20. Marr KA, Kong L, Fowler VG et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998; 54: 1684-1689.
21. Chang FY, Macdonald BB, Peacock JE et al. A prospective multicenter study of Staphylococcus aureus bacteremia: Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82: 322-332.
22. Fatkenheuer G, Preuss M, Salzberger B et al. Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2004; 23: 157-162.
23. Tiemersma EW, Bronzwaer SL, Lyytikainen O et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10: 1627-1634.
24. Marr KA. Staphylococcus aureus bacteremia in patients undergoing hemodialysis. Semin Dial 2000; 13: 23-29.
25. Schwab SJ, Harrington JT, Singh A et al. Vascular access for hemodialysis. Kidney Int 1999; 55: 2078-2090.
26. Pisoni RL, Young EW, Dykstra DM et al. Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 2002; 61: 305-316.
27. Berns JS, Tokars JI. Preventing bacterial infections and antimicrobial resistance in dialysis patients. Am J Kidney Dis 2002; 40: 886-898.
28. Anonymous. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37 (suppl 1): S137-S181.
29. Beathard GA. Catheter management protocol for catheter-related bacteremia prophylaxis. Semin Dial 2003; 16: 403-405.